Dihydrobenzoindazoles

1. A compound according to Formula I

or a pharmaceutically acceptable salt thereof wherein

R1 is phenyl, optionally substituted with halogen, nitro, (1-6C)alkyl, (2-6C)alkenyl, (1-6C)alkoxy, (2-5C)heteroaryl, (3-6C)cycloalkyl; or

R1 is (2-5C)heteroaryl, optionally fused with a benzo group and optionally substituted at the heteroaryl or benzo group with halogen or (1-4C)alkyl; or

R1 is (2-5C)heterocycloalkyl or (2-5C)heterocycloalkenyl, both optionally substituted with one or more fluorines, (1-2C)alkyl groups or (1-3C)alkoxy groups;

R2 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy or (1-4C)alkylsulfonamino, all alkyl groups optionally substituted with one or more hydroxyl or fluorines; or

R2 is (2-5C)heteroaryl, R5-carbonylamino or R5-aminocarbonyl

R3 (1-6C)alkoxy or hydroxyl;

R4 is (di)[(1-6C)alkyl]amino; or R4 is pyrrolidin-1-yl, optionally substituted with one or more (1-2C)alkyl groups; or R4 is diazacycloheptyl, optionally substituted with (1-6C)alkylcarbonyl or (3-6C)cycloalkylcarbonyl; or

R4 is

R5 is (2-5C)heteroaryl or (1-6C)alkyl, both optionally substituted with one or more hydroxyl groups or halogens; or

R5 is (2-5C)heterocycloalkyl(1-4C)alkyl, the heterocycloalkyl group optionally substituted with (1-4C)alkyl or (di)[(1-4C)alkyl]amino(1-4C)alkyl; and

R6 is (1-6C)alkyl.

2. The compound according to claim 1 wherein R2 is (1-6C)alkoxy, (2-5C)heteroaryl, R5-carbonylamino or (1-4C)alkylsulfonamino.

3. The compound according to claim 2 wherein R2 is (1-4C)alkoxy.

4. The compound according to claim 1 wherein R3 is methoxy.

5. The compound according to claim 1 wherein R4 is 1,4-diazacycloheptyl, optionally substituted at the nitrogen at position 4 with (1-6C)alkylcarbonyl or (3-6C)cycloalkylcarbonyl.

6. The compound according to claim 1 wherein R4 is di[(1-6C)alkyl]amino.

7. The compound according to claim 1 wherein R1 is phenyl, optionally substituted with halogen, nitro, (1-6C)alkyl, (2-6C)alkenyl, (1-6C)alkoxy, (3-6C)cycloalkyl or R1 is thienyl.

8. A pharmaceutical composition made by combining a compound according to claim 1 , or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

9. A pharmaceutical composition according to claim 8 , which further comprises at least one additional therapeutically active agent, wherein the additional therapeutic agent is a gonadotropin agonist or a GnRH modulator.

10. A method of ovarian stimulation comprising administering a therapeutically effective amount of a compound according to claim 1 to a patient in need thereof.

11. A method of treating a fertility disorder comprising administering a therapeutically effective amount of a compound according to claim 1 to a patient in need thereof.